GB 102
Alternative Names: GB-102Latest Information Update: 12 Oct 2023
At a glance
- Originator Reyon Pharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Coronary artery disease; Kidney disorders
Most Recent Events
- 20 Sep 2023 Preclinical trials in Coronary artery disease in South Korea (Parenteral) before September 2023 (Reyon Pharmaceutical pipeline, September 2023)
- 20 Sep 2023 Preclinical trials in Kidney disorders in South Korea (Parenteral) before September 2023 (Reyon Pharmaceutical pipeline, September 2023)